- Home
- BYFC vs SERA Comparison
BYFC vs SERA Comparison
Compare BYFC & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BYFC | SERA |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.3M | 75.2M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BYFC | SERA |
|---|---|---|
| Price | $10.04 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.2K | ★ 32.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $184,000.00 | $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | $202.20 | ★ N/A |
| Revenue Growth | ★ 18.71 | 5.19 |
| 52 Week Low | $5.51 | $1.56 |
| 52 Week High | $10.46 | $3.95 |
Technical Indicators
Market Signals| Indicator | BYFC | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 47.56 |
| Support Level | $9.29 | $1.68 |
| Resistance Level | $10.42 | $2.07 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 78.70 | 19.60 |
Price Performance
Historical ComparisonAbout BYFC Broadway Financial Corporation
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.